Economic Observation Network Junshengtai Pharma-B is currently in negotiations with potential partners regarding the domestic authorization and commercialization of indications related to its core products. The types of funds involved in the cooperation have been preliminarily clarified. According to the announcement of the company on July 10, 2026, the company is negotiating with "several potential partners" on the potential authorization and commercialization cooperation of HTD1801's first listing indication (type 2 diabetes) in China Potential cooperation may involve down payments, milestone payments, and sales commissions. This is currently the most clear information on the progress of cooperation.

The above content is based on publicly available information and does not constitute investment advice.